Kane Biotech Inc.
KNE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 231.71% | 222.95% | -31.50% | -27.01% | 7.32% |
| Total Depreciation and Amortization | -10.05% | -6.55% | -10.75% | -9.10% | -15.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -759.58% | -958.39% | 145.95% | 105.75% | 155.69% |
| Change in Net Operating Assets | -219.86% | -266.30% | 1,116.36% | 404.79% | -19.28% |
| Cash from Operations | -229.01% | -187.90% | -2.02% | -3.73% | 39.24% |
| Capital Expenditure | -994.44% | -1,408.33% | -135.56% | 1.45% | 88.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -374.51% | -263.41% | -1.95% | -7.83% | 49.28% |
| Cash from Investing | 8,046.68% | 5,929.28% | -9.70% | -6.90% | 52.68% |
| Total Debt Issued | -100.00% | -1.18% | -67.06% | -20.78% | -30.26% |
| Total Debt Repaid | -1,775.17% | -2,734.04% | -103.79% | 7.64% | 49.84% |
| Issuance of Common Stock | -44.02% | -- | -59.01% | -69.62% | -68.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 296.91% | 1,263.89% | 764.89% | 578.16% | 130.88% |
| Cash from Financing | -355.74% | -716.22% | -13.89% | -6.70% | -27.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -699.16% | 11.84% | -452.87% | -1,803.65% | 2,826.00% |
